Article

Genetic Testing for GI Cancers: Preventative and Diagnostic

There can be many benefits for patients with gastrointestinal cancers, as well as their loved ones, to undergo genetic testing.

Undergoing genetic testing for gastrointestinal (GI) cancers can be both preventative and diagnostic, explained Matthew Yurgelun, M.D., assistant professor of medicine at the Dana-Farber Cancer Institute.

If someone is already diagnosed with cancer, undergoing genetic and/or molecular testing can offer information about other cancers that they may be at risk for developing, as well as treatment options they may respond best to. For example, patients whose tumors test positive for microsatellite instability-high (MSI-H) status are more likely to have better responses to certain types of immunotherapy.

Genetic counseling can also play a preventative and proactive role for those without cancer, especially for those who have family members with a diagnosis.

Related Videos
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker